- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Authors
Latest:
Analyzing the Safety Data of JAK InhibitorsPanelists discuss the key safety data observed with each of the three Janus kinase (JAK) inhibitors for alopecia areata (AA), highlighting potential adverse effects and how these impact clinical decision-making.
Latest:
Contributor: Reframing Health Literacy—A Systemic Driver of Equity and OutcomesImproving health literacy is essential for promoting health equity, reducing preventable illness, and making health care more effective.
Latest:
Addressing the Opioid CrisisThe authors highlight the diversity of multiagency electronic data-sharing approaches and present a case study addressing the opioid crisis
Latest:
Hospital Outcomes of Male Breast Cancer in the United StatesThis is the first study to estimate the hospital lengths of stay and costs of male breast cancer at the US population level.
Latest:
Contributor: Yearly Trends in Coverage Rates for GLP-1 RAs in Weight LossExplore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.
Latest:
Service Line Care Delivery Model for COVID-19 Patient-Centric CareThe authors provide steps hospitals can take to align their care delivery model to effectively meet the demands of a public health crisis such as the current pandemic.
Latest:
Implementing Multistate Behavioral Health Pay-for-Performance Initiatives in Medicaid Managed CareThe authors describe a pay-for-performance initiative targeting behavioral health providers, which was introduced by a large Medicaid managed care organization across multiple states.
Latest:
Baloxavir vs Oseltamivir: Reduced Utilization and Costs in InfluenzaBaloxavir, compared with oseltamivir, was associated with lower health care resource utilization and costs in patients with influenza, particularly those at high risk of secondary complications.
Latest:
Provider Barriers in Uptake of Biosimilars: Case Study on FilgrastimPrevious studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.
Latest:
Reducing Readmissions in the Safety Net Through AI and AutomationArtificial intelligence (AI) and electronic health record–based automation tools helped a safety-net health system meet performance-based readmission metrics, thereby retaining critical funding while improving clinical and equity outcomes.
Latest:
Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology PracticeReal-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.
Latest:
Addressing Virtual Care Disparities for Patients With Limited English ProficiencyWith increased use of virtual care due to the COVID-19 pandemic, the following recommendations address disparities for patients with limited English proficiency.
Latest:
Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 DiabetesAnalysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.
Latest:
Cost Sharing for Oral Lenvatinib Among Commercially Insured PatientsAmong a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.
Latest:
Adverse Effect Management in the COCOON Trial for EGFR-Mutated NSCLC: Jill FeldmanJill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.
Latest:
Predicting Opioid Use Disorder and Associated Risk Factors in a Medicaid Managed Care PopulationA Medicaid managed care organization developed a machine learning model to identify opioid use disorder (OUD) risk factors and predict OUD incidence in its multistate population.
Latest:
Contributor: How Pharmacists and Providers Can Improve Patient CarePharmacists and pharmacies can be doing more to help with medication management for their patients.
Latest:
Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 CongressAt the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Latest:
Improving Pain Clinic Outcomes With Preappointment Surveys: Data-Driven Policy ChangeImplementing a policy change to require preappointment surveys before scheduling initial clinic evaluations can improve wait-list times and show rates.
Latest:
Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment CostsThe authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.
Latest:
Statin Prescribing Patterns in Patient-Centered Medical Home Patients With NAFLDIn this study, authors assessed the proportion of patients with nonalcoholic fatty liver disease (NAFLD) receiving prescriptions for statins in primary care.
Latest:
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent IndicationsThe Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
Latest:
Bundled Payments Lead to Quality Improvements in Hospitals’ Skilled Nursing Facility Referral NetworksThe Bundled Payments for Care Improvement program was associated with improved quality of skilled nursing facilities in hospital referral networks for patients undergoing surgery for joint replacement.
Latest:
Stakeholder Insights on rtCGM in T2D Population Health ManagementLeading payer and health system stakeholders reviewed literature and shared insights on the value of real-time continuous glucose monitoring (rtCGM) in type 2 diabetes (T2D) population health.
Latest:
Trispecifics in Context: Hype vs ReadinessA panelist emphasizes that while trispecific antibodies offer near-perfect response rates and convenient monthly dosing that could improve quality of life, careful assessment of adverse effects like infections and taste disturbances is crucial—especially for lower-risk patients—making patient preference and physician judgment key in determining their optimal use, with high-risk patients with heavily pretreated disease poised to benefit most.
Latest:
Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024Panelists share their final thoughts on bispecific therapies in B-cell lymphomas based on insights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024.
Latest:
Implementation of the Accountable Health Communities Model in ArizonaThe Accountable Health Communities Model facilitates multisector coordination. Implementation science elucidated the contextual factors that facilitated the use of this model in Arizona.
